GlassScriptPhysician profile
Cody Burr Clinton
NPI 1235425190
$1,652.89
in general payments reported to CMS, 2019-2025
15 companies · $57.68 in 2025
The $57.68 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $110 · 2021: $152 · 2022: $16.49 · 2023: $66.87 · 2024: $922 · 2025: $57.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $660 · Food and Beverage: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $659.97 |
| Food and Beverage | $386.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $871.31 | 2024 | Iovera |
| Ferring Pharmaceuticals INC. | $260.99 | 2019-2021 | |
| Fidia Pharma USA INC. | $87.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $71.96 | 2019-2020 | |
| Depuy Synthes Sales INC. | $70.02 | 2019-2025 | Peak, Monovisc, Orthovisc |
| Abbvie INC. | $68.86 | 2021 | |
| Amneal Pharmaceuticals LLC | $39.95 | 2019-2020 | |
| Stryker Corporation | $33.34 | 2025 | T2 Alpha |
| Amgen INC. | $30.76 | 2024 | Repatha |
| Bioventus LLC | $25.24 | 2023 | Durolane |
| Impel Pharmaceuticals INC. | $24.77 | 2023 | Trudhesa |
| Impel Pharmaceuticals LLC | $19.97 | 2024 | Trudhesa |
| Avanos Medical | $16.86 | 2023 | Trivisc Sodium Hyaluronate |
| Biohaven Pharmaceutical Holding Company LTD. | $16.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Clinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.